Search - tctmd.com

Displaying 221 - 240 of 315

Sort: Relevancy | Date

Presentation TCT 2013

From Xience V to Prime to Xpedition: Stent Design Evolution and Clinical Trial Results (SPIRIT and Others)

Presenter: James Hermiller Jr

October 28, 2013

Presentation TCT 2013

Latest Results from ABSORB Extend: Comparison with Xience

Presenter: Bernard Chevalier

October 27, 2013

News Daily News

Paclitaxel-Eluting Balloon-Plus-BMS Strategy Fares Poorly vs. EES in De Novo Stenosis

October 15, 2013

News Daily News

La Estrategia Balón liberador de Paclitaxel + SMD es Pobre comparada con los SLE en el Tratamiento de la Estenosis De Novo

October 15, 2013

News Daily News

EXECUTIVE: Xience Performs Well in Patients with Less Complex Multivessel Disease

October 15, 2013

News Daily News

EXECUTIVE: Xience Funciona Bien en Pacientes con Enfermedad Multivaso Menos Compleja

October 15, 2013

News Daily News

EXECUTIVE：依维莫司在治疗非复杂多支病变中效果良好

October 15, 2013

Presentation

Elutax Paclitaxel-Eluting Balloon (PEB) Followed by BMS Compared with Xience V DES for Coronary De Novo Stenosis

Presenter: F. Liistro

October 14, 2013

Presentation

A Clinical and Angiographic Study of the Xience V EES in the Treatment of Multivessel CAD

Presenter: Flavio Ribichini

September 23, 2013

News Daily News

SPIRIT Meta-analysis Confirms Overall Superiority of Xience over Taxus

September 20, 2013

News Daily News

Meta-análisis de SPIRIT confirma superioridad total de Xience sobre Taxus

September 20, 2013

News Daily News

Contemporary ZES Perform Well in Treating In-Stent Restenosis

August 14, 2013

News Conference News EuroPCR 2013

EuroPCR 2013: From Cutting-Edge Devices to the Clinical Challenges

Caitlin E. Cox

May 29, 2013

News Daily News

TWENTE: Still Few Differences between ZES and EES at 2 Years

L.A. McKeown

May 03, 2013

News Daily News

TWENTE: Sigue habiendo Pequeñas Diferencias entre los SLZ y los SLE a los 2 Años

L.A. McKeown

May 03, 2013

Presentation ACC 2013

Three-Year Results of the PLATINUM Randomized Trial Comparing Platinum Chromium PROMUS Element and Cobalt Chromium PROMUS/XIENCE V Everolimus-Eluting Stents

Presenter: Ian T. Meredith

March 09, 2013

News Conference News ACC 2013

Is Nobori NEXT? Biodegradable-Polymer DES Noninferior to EES

Jason Kahn

March 09, 2013

Presentation TCT 2013

Randomized comparison of Biolimus-eluting (Nobori) and Everolimus-eluting (Xience/Promus) stents in patients with multivessel coronary artery disease: 12-month follow-up data...

Presenter: Peter Smits, A. J. van Boven, Mariano Valdes, Antonio Serra, Jean-Jacques Goy, V. Voudris, Ramiro Trillo, J. M. Vazquez, Peter den Heijer, Ton Slagboom, A.G. Vuillomenet

January 31, 2013

Presentation TCT 2013

Clinical Outcome in Chinese Patients with Long Lesion or Small Vessel / Multivessel Disease Receiving XIENCE V Everolimus-Eluting Stent: Early Results from the SEEDS Study

Presenter: Bo Xu, Yuejin Yang, Yaling Han, Bao Li, Qiang Liu, Guoying Zhu, Junyu Cui, Lang Li, Shuzheng Lu

January 31, 2013

News Daily News

La Duración Ideal de la Terapia Antiplaquetaria Doble podría Depender del Tipo de Stent

Jason Kahn

January 22, 2013

Advertisement

From Xience V to Prime to Xpedition: Stent Design Evolution and Clinical Trial Results (SPIRIT and Others)

Latest Results from ABSORB Extend: Comparison with Xience

Paclitaxel-Eluting Balloon-Plus-BMS Strategy Fares Poorly vs. EES in De Novo Stenosis

La Estrategia Balón liberador de Paclitaxel + SMD es Pobre comparada con los SLE en el Tratamiento de la Estenosis De Novo

EXECUTIVE: Xience Performs Well in Patients with Less Complex Multivessel Disease

EXECUTIVE: Xience Funciona Bien en Pacientes con Enfermedad Multivaso Menos Compleja

EXECUTIVE：依维莫司在治疗非复杂多支病变中效果良好

Elutax Paclitaxel-Eluting Balloon (PEB) Followed by BMS Compared with Xience V DES for Coronary De Novo Stenosis

A Clinical and Angiographic Study of the Xience V EES in the Treatment of Multivessel CAD

SPIRIT Meta-analysis Confirms Overall Superiority of Xience over Taxus

Meta-análisis de SPIRIT confirma superioridad total de Xience sobre Taxus

Contemporary ZES Perform Well in Treating In-Stent Restenosis

EuroPCR 2013: From Cutting-Edge Devices to the Clinical Challenges

TWENTE: Still Few Differences between ZES and EES at 2 Years

TWENTE: Sigue habiendo Pequeñas Diferencias entre los SLZ y los SLE a los 2 Años

Three-Year Results of the PLATINUM Randomized Trial Comparing Platinum Chromium PROMUS Element and Cobalt Chromium PROMUS/XIENCE V Everolimus-Eluting Stents

Is Nobori NEXT? Biodegradable-Polymer DES Noninferior to EES

Randomized comparison of Biolimus-eluting (Nobori) and Everolimus-eluting (Xience/Promus) stents in patients with multivessel coronary artery disease: 12-month follow-up data...

Clinical Outcome in Chinese Patients with Long Lesion or Small Vessel / Multivessel Disease Receiving XIENCE V Everolimus-Eluting Stent: Early Results from the SEEDS Study

La Duración Ideal de la Terapia Antiplaquetaria Doble podría Depender del Tipo de Stent

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content